Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
CytomX Therapeutics Inc (CTMX) is a clinical-stage biopharmaceutical pioneer developing conditionally activated cancer therapies through its probody technology platform. This dedicated news hub provides investors and researchers with essential updates on clinical advancements, strategic collaborations, and therapeutic innovations in oncology.
Access real-time updates on CTMX's probody-based candidates, including antibody drug conjugates and T-cell engagers. The platform centralizes critical developments such as trial milestones, partnership expansions with industry leaders like Astellas and Merck, and financial disclosures - all vital for informed analysis of this innovative oncology company.
Key content categories include clinical program progress, regulatory updates, scientific presentations, and corporate financial results. Each update is curated to highlight how CTMX's tumor-activated therapies aim to improve cancer treatment safety profiles while maintaining therapeutic efficacy.
Bookmark this page for streamlined access to verified CTMX developments. Regularly updated with official press releases and objective reporting, it serves as your primary resource for tracking advancements in conditionally activated cancer immunotherapies.
Regeneron Pharmaceuticals and CytomX Therapeutics have entered a significant collaboration to develop next-generation bispecific immunotherapies. CytomX will receive an upfront payment of $30 million and could earn up to $2 billion in future milestones. The collaboration focuses on utilizing CytomX's Probody® technology and Regeneron's Veloci-Bi® platform to create therapies that activate specifically in tumor environments, potentially improving treatment efficacy and reducing side effects. The partnership aims to expand cancer treatment options significantly.
CytomX Therapeutics (CTMX) reported its Q3 2022 financial results and business updates, highlighting advancements in its oncology pipeline. The company is progressing on CX-2051 and CX-801, both slated for IND submissions in 2023. CX-904 is currently in Phase 1, while collaborations with Bristol Myers Squibb on BMS-986249 and AbbVie on CX-2029 continue in Phase 2. Financially, cash reserves decreased to $194.3 million from $305.2 million year-over-year, with revenue of $16.9 million. R&D expenses rose to $30.4 million, reflecting restructuring expenses.
CytomX Therapeutics (Nasdaq: CTMX) announced the upcoming presentation of preclinical data for CX-801, a masked interferon alpha-2b therapeutic candidate, at the SITC Annual Meeting in Boston. CX-801 aims to improve tolerability and efficacy in treating tumors by leveraging a favorable therapeutic index. The company plans to file an IND for CX-801 in the second half of 2023, with ongoing exploration of its potential in both responsive and non-responsive tumor types. The presentation is scheduled for November 10-11, 2022, detailing the benefits of CX-801 combined with PD-L1 blockade.
CytomX Therapeutics (Nasdaq: CTMX) has announced participation in two key investor conferences in November. CEO Sean McCarthy will engage in a virtual fireside chat for the BMO Biopharma Spotlight Series: Oncology Day on November 9 at 11:30 a.m. ET, followed by a session at the Piper Sandler 34th Annual Healthcare Conference on November 29 at 8:30 a.m. ET in New York. A live webcast will be available on CytomX’s website, where management will also hold one-on-one investor meetings.
CytomX Therapeutics (CTMX) will announce its third quarter 2022 financial results on November 8, 2022, after market close. Following the results, a conference call will be hosted at 5:00 p.m. ET to discuss the findings and provide updates. The company focuses on conditionally activated oncology therapeutics, with a pipeline including seven therapeutic candidates such as CX-2029 and Probody therapeutics partnered with leading biopharmaceutical companies. For further details, visit CytomX's website.
CytomX Therapeutics (NASDAQ: CTMX) announced the presentation of updated Phase 1 results for BMS-986249, its Probody therapeutic designed to target CTLA-4, at the ESMO 2022 Congress. Collaborator Bristol Myers Squibb reported encouraging findings, including a complete response in melanoma and a partial response in colorectal cancer. The ongoing Phase 2 trial aims to evaluate BMS-986249's efficacy against conventional ipilimumab. CytomX continues to advance a diverse pipeline of oncology candidates with multiple collaborations, enhancing its presence in the oncology market.
CytomX Therapeutics presented advancements in its ADC portfolio, particularly CX-2051, at the World ADC conference in San Diego on September 6-9, 2022. CX-2051 is a conditionally activated ADC, targeting EpCAM, aimed at improving treatment for EpCAM-expressing cancers. The payload is camptothecin, which has shown safe clinical activity. CytomX's strategy focuses on leveraging its Probody technology to enhance therapeutic efficacy while minimizing toxicity. Upcoming plans include submissions for investigational new drug applications in the latter half of 2023.
CytomX Therapeutics (CTMX) reported its Q2 2022 financial results, highlighting a strategic restructuring aimed at focusing on its early-stage pipeline and extending its cash runway to 2025. The company plans to submit INDs for two product candidates in 2023 and is advancing partnered clinical programs including CX-904 with Amgen and BMS-986249 with Bristol Myers Squibb. Cash and investments stood at $228 million, up from $16 million in revenue year-over-year. R&D expenses increased to $31 million, attributed to higher personnel costs.
CytomX Therapeutics (Nasdaq: CTMX), a leader in oncology therapeutics, announced CEO Sean McCarthy will participate in two investor conferences this August. The conferences are the BTIG Biotechnology Conference on August 9, 2022, and the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022, where he will take part in a panel discussion at 2:20 p.m. ET. A live webcast of the Wedbush panel will be available on CytomX’s website. The company focuses on conditionally activated biologics, with a robust pipeline including candidates for various cancers.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) will release its Q2 2022 financial results on August 4, 2022, after U.S. market closure. A conference call will follow at 5:00 p.m. ET to discuss the results and provide corporate updates. Participants can join via the company’s webcast.
CytomX focuses on oncology therapeutics, leveraging its Probody® technology. The pipeline includes seven candidates, with three in Phase 2 studies for various cancer types.
FAQ
What is the current stock price of Cytomx Therapeutics (CTMX)?
What is the market cap of Cytomx Therapeutics (CTMX)?
